Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome

References

• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ottobre 20;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Cao H, Su S, Yang Q, et al. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients. Lipids Health Dis. 2021;20(1):16.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J. 2010;31(8):1000–1006.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650–656.e3.
   PubMed Web of Science ®Google Scholar
• Fernández‐Armenteros JM, Gómez‐Arbonés X, Buti‐Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population‐based study. J Eur Acad Dermatol Venereol. 2019;33(1):128–135.
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J Invest Dermatol. 2013;133(10):2347–2354.
   PubMed Web of Science ®Google Scholar
• Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant. J Am Acad Dermatol. 2015;72(4):599–605.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Stathopoulou A, Gregoriou S. Small molecules and biologics in the treatment of nail psoriasis. Skin Appendage Disord. 2020;6(3):134–141.
   PubMed Web of Science ®Google Scholar
• Amin M, No DJ, Egeberg A, et al. Choosing first-line biologic treatment for moderate-to-severe Psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1–13.
   PubMed Web of Science ®Google Scholar
• Thatiparthi A, Martin A, Liu J, et al. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425–442.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med Front Med (Lausanne). 2015;21(2): 1.
   Google Scholar
• De Brito M, Yiu ZZN. Cardiovascular safety of biologics targeting interleukin (IL)-12 and/or IL-23: what does the evidence say? Am J Clin Dermatol. 2021;22(5):587–601.
   PubMed Web of Science ®Google Scholar
• Abbas A, Gregersen I, Holm S, et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015;46(3):793–799.
   PubMed Web of Science ®Google Scholar
• Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–728.
   PubMed Web of Science ®Google Scholar
• Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging. 2020;13(9):e011199.
   PubMed Web of Science ®Google Scholar
• Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging. 2010;26(6):631–640.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Notarsanto I, de Pinto GD, et al. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med. 2010;5(6):495–500.
   PubMed Web of Science ®Google Scholar
• Ramonda R, Puato M, Punzi L, et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine. 2014;81(5):421–425.
   PubMed Web of Science ®Google Scholar
• Von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu YD, Foroughi N, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–1039.
   PubMedGoogle Scholar
• Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667–2676.
   PubMed Web of Science ®Google Scholar
• Smith E, Prasad KMR, Butcher M, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E–deficient mice. Circulation. 2010;121(15):1746–1755.
   PubMed Web of Science ®Google Scholar
• Jia Y, Gan Y, He C, et al. The mechanism of skin lipids influencing skin status. J Dermatol Sci. 2018;89(2):112–119.
   PubMed Web of Science ®Google Scholar
• Kasikara C, Doran AC, Cai B, et al. The role of non-resolving inflammation in atherosclerosis. J Clin Invest. 2018;128(7):2713–2723.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med. 2009;47(7):891–905.
   PubMed Web of Science ®Google Scholar
• Zwain A, Aldiwani M, Taqi H. The association between psoriasis and cardiovascular diseases. Eur Cardiol Rev. 2021; 16:e19.
   PubMed Web of Science ®Google Scholar
• Liu-Wu Y, Hurt-Camejo E, Wiklund O. Lysophosphatidylcholine induces the production of IL-1β by human monocytes. Atherosclerosis. 1998;137(2):351–357.
   PubMed Web of Science ®Google Scholar
• Carneiro AB, Iaciura BMF, Nohara LL, et al. Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation. Marinho CRF, curatore. PLoS ONE. 2013;8(9):e76233.
   PubMed Web of Science ®Google Scholar
• Nordlohne J, von Vietinghoff S. Interleukin 17A in atherosclerosis – regulation and pathophysiologic effector function. Cytokine. 2019;122:154089.
   PubMed Web of Science ®Google Scholar
• Von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096.
   PubMed Web of Science ®Google Scholar
• Akhavanpoor M, Akhavanpoor H, Gleer CA, et al. The two faces of interleukin-17A in atherosclerosis. Curr Drug Targets. 2017;18(7):863–873.
   PubMed Web of Science ®Google Scholar
• Wu L, Ong S, Talor MV, et al. Cardiac fibroblasts mediate IL-17A–driven inflammatory dilated cardiomyopathy. J Exp Med. 2014;211(7):1449–1464.
   PubMed Web of Science ®Google Scholar
• Madhur MS, Funt SA, Li L, et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein E–deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(7):1565–1572.
   PubMed Web of Science ®Google Scholar
• Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577.
   PubMed Web of Science ®Google Scholar
• Yong K, Dogra G, Boudville N, et al. Interleukin-12 is associated with arterial stiffness in healthy individuals. Am J Hypertens. 2013;26(2):159–162.
   PubMed Web of Science ®Google Scholar
• Booth A, Magnuson A, Fouts J, et al. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26(1):25–42.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–238.
   PubMed Web of Science ®Google Scholar
• Chehimi M, Vidal H, Eljaafari A. Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med. 2017;6(7):68.
   PubMed Web of Science ®Google Scholar
• Burhans MS, Hagman DK, Kuzma JN, et al. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol. 2018;9(1):1–58.
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917–925.
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: results of a randomised controlled trial. Br J Dermatol. 2022 Jun;186(6):942-954.
   Web of Science ®Google Scholar
• Borroni RG, Malagoli P, Gargiulo L, et al. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021;101(11):adv00605.
   PubMedGoogle Scholar
• Hansel K, Zangrilli A, Bianchi L, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e169–e170.
   PubMed Web of Science ®Google Scholar
• Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Girolomoni G, et al. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117.
   PubMed Web of Science ®Google Scholar
• Stanescu AMA, Simionescu AA, Florea M, et al. Is metformin a possible beneficial treatment for psoriasis? A scoping review. J Pers Med. 2021;11(4):251.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Paul C, Puig L, et al. Safety of Ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther. 2020;10(1):133–150.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Chiricozzi A, Cinotti E, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opin Biol Ther. 2022;22(3):367–376.
   PubMed Web of Science ®Google Scholar
• Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–945.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022 Feb;157(Suppl. 1 to No. 1):1–78.
   PubMedGoogle Scholar